Logo image of DAWN

DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Fundamental Analysis

NASDAQ:DAWN - Nasdaq - US23954D1090 - Common Stock - Currency: USD

6.27  0 (0%)

After market: 6.32 +0.05 (+0.8%)

Fundamental Rating

4

Overall DAWN gets a fundamental rating of 4 out of 10. We evaluated DAWN against 561 industry peers in the Biotechnology industry. While DAWN has a great health rating, there are worries on its profitability. DAWN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DAWN has reported negative net income.
DAWN had a negative operating cash flow in the past year.
DAWN had negative earnings in each of the past 5 years.
DAWN had a negative operating cash flow in each of the past 5 years.
DAWN Yearly Net Income VS EBIT VS OCF VS FCFDAWN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.39%, DAWN belongs to the top of the industry, outperforming 80.39% of the companies in the same industry.
DAWN has a Return On Equity of -18.99%. This is amongst the best in the industry. DAWN outperforms 86.63% of its industry peers.
Industry RankSector Rank
ROA -16.39%
ROE -18.99%
ROIC N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
DAWN Yearly ROA, ROE, ROICDAWN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

DAWN's Gross Margin of 95.98% is amongst the best of the industry. DAWN outperforms 94.65% of its industry peers.
The Profit Margin and Operating Margin are not available for DAWN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DAWN Yearly Profit, Operating, Gross MarginsDAWN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

DAWN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DAWN has more shares outstanding
Compared to 5 years ago, DAWN has more shares outstanding
There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DAWN Yearly Shares OutstandingDAWN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DAWN Yearly Total Debt VS Total AssetsDAWN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 3.43 indicates that DAWN is not in any danger for bankruptcy at the moment.
DAWN's Altman-Z score of 3.43 is fine compared to the rest of the industry. DAWN outperforms 77.18% of its industry peers.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.43
ROIC/WACCN/A
WACC10.02%
DAWN Yearly LT Debt VS Equity VS FCFDAWN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 7.66 indicates that DAWN has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.66, DAWN is doing good in the industry, outperforming 71.66% of the companies in the same industry.
A Quick Ratio of 7.61 indicates that DAWN has no problem at all paying its short term obligations.
DAWN has a better Quick ratio (7.61) than 71.84% of its industry peers.
Industry RankSector Rank
Current Ratio 7.66
Quick Ratio 7.61
DAWN Yearly Current Assets VS Current LiabilitesDAWN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

DAWN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.82%, which is quite impressive.
EPS 1Y (TTM)43.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, DAWN will show a very strong growth in Earnings Per Share. The EPS will grow by 27.59% on average per year.
Based on estimates for the next years, DAWN will show a very strong growth in Revenue. The Revenue will grow by 41.20% on average per year.
EPS Next Y20.92%
EPS Next 2Y24.08%
EPS Next 3Y31.95%
EPS Next 5Y27.59%
Revenue Next Year23.82%
Revenue Next 2Y36.06%
Revenue Next 3Y45.21%
Revenue Next 5Y41.2%

3.3 Evolution

DAWN Yearly Revenue VS EstimatesDAWN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DAWN Yearly EPS VS EstimatesDAWN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DAWN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DAWN Price Earnings VS Forward Price EarningsDAWN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DAWN Per share dataDAWN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

DAWN's earnings are expected to grow with 31.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.08%
EPS Next 3Y31.95%

More info and screens

0

5. Dividend

5.1 Amount

DAWN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (5/23/2025, 9:25:48 PM)

After market: 6.32 +0.05 (+0.8%)

6.27

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)07-08 2025-07-08/bmo
Inst Owners94.33%
Inst Owner Change1.41%
Ins Owners2.14%
Ins Owner Change0.03%
Market Cap635.46M
Analysts82.67
Price Target29.58 (371.77%)
Short Float %21.23%
Short Ratio13.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.9%
Min EPS beat(2)-73.33%
Max EPS beat(2)11.53%
EPS beat(4)2
Avg EPS beat(4)6.31%
Min EPS beat(4)-73.33%
Max EPS beat(4)93.47%
EPS beat(8)5
Avg EPS beat(8)4.26%
EPS beat(12)7
Avg EPS beat(12)-0.25%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.71%
Min Revenue beat(2)-16.43%
Max Revenue beat(2)3.01%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.58%
PT rev (3m)-19.69%
EPS NQ rev (1m)-2.02%
EPS NQ rev (3m)-40.03%
EPS NY rev (1m)11.54%
EPS NY rev (3m)-29.21%
Revenue NQ rev (1m)-1.49%
Revenue NQ rev (3m)-8.79%
Revenue NY rev (1m)-6.21%
Revenue NY rev (3m)-8.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.84
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.3
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS1.29
BVpS4.96
TBVpS4.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.39%
ROE -18.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.98%
FCFM N/A
ROA(3y)-35.78%
ROA(5y)-50.98%
ROE(3y)-38.78%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 949.68%
Cap/Sales 14.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.66
Quick Ratio 7.61
Altman-Z 3.43
F-Score5
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)352.72%
Cap/Depr(5y)301.63%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.39%
EPS Next Y20.92%
EPS Next 2Y24.08%
EPS Next 3Y31.95%
EPS Next 5Y27.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year23.82%
Revenue Next 2Y36.06%
Revenue Next 3Y45.21%
Revenue Next 5Y41.2%
EBIT growth 1Y-5.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.75%
EBIT Next 3Y27.24%
EBIT Next 5YN/A
FCF growth 1Y33.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.81%
OCF growth 3YN/A
OCF growth 5YN/A